Northwest Biotherapeutics, Inc. (NWBO)
Market Cap | 1.17B |
Revenue (ttm) | 1.69M |
Net Income (ttm) | -242.65M |
Shares Out | 747.75M |
EPS (ttm) | -0.36 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | February 25 |
Last Price | $1.47 |
Previous Close | $1.50 |
Change ($) | -0.03 |
Change (%) | -1.70% |
Day's Open | 1.52 |
Day's Range | 1.43 - 1.58 |
Day's Volume | 1,808,022 |
52-Week Range | 0.141 - 2.51 |
News
NWBO has run an 18-year long trial in GBM, one of the deadliest of cancers. It has been mired in controversies, and it has no cash.
In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0.
About NWBO
Northwest Biotherapeutics, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It is developing DCVax-L that is in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, which is in Phase I/II clinical trials to treat various inoperable solid tumor cancers. The company was foun... [Read more...]
Industry Biotechnology | Founded 1996 |
CEO Linda Powers | Employees 17 |
Stock Exchange OTCMKTS | Ticker Symbol NWBO |
Financial Performance
In 2019, NWBO's revenue was $2.41 million, an increase of 484.95% compared to the previous year's $412,000. Losses were -$20.30 million, -43.30% less than in 2018.